Selective inactivity of pyrazinamide against tuberculosis in C3HeB/FeJ mice is best explained by neutral pH of caseum

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 2, 2016, Pages 735-743

  Lanoix, Jean Philippe ^a,b   Ioerger, Thomas ^c   Ormond, Aimee ^a   Kaya, Firat ^d   Sacchettini, James ^c   Dartois, Véronique ^d   Nuermberger, Eric ^a,e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSERM   (France)

^c TEXAS A AND M UNIVERSITY   (United States)

^d PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PYRAZINAMIDE; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BALB/C NUDE MOUSE; C3HEB/FE MOUSE; COLONY FORMING UNIT; CONCENTRATION AT STEADY-STATE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; EC50; EPITHELIAL LINING FLUID; FEMALE; LUNG LESION; LUNG TUBERCULOSIS; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; STEADY STATE; ANIMAL; ANTIBIOTIC RESISTANCE; BACTERIAL GENOME; BAGG ALBINO MOUSE; C3H MOUSE; DISEASE MODEL; DRUG EFFECTS; GENETICS; LUNG; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PATHOLOGY; PHYSIOLOGY; TUBERCULOSIS, PULMONARY;

ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; GENOME, BACTERIAL; HYDROGEN-ION CONCENTRATION; LUNG; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; TUBERCULOSIS, PULMONARY;

EID: 84957927261     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01370-15     Document Type: Article

References (48)

1. British Thoracic and Tuberculosis Association. 1976. Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association. Lancet ii:1102-1104.
2. British Thoracic Society. 1984. A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. Br J Dis Chest 78:330-336.
3. Zhang Y, Mitchison D. 2003. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 7:6-21.
4. Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE, Wang H, Zhang W, Zhang Y. 2011. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333:1630-1632. http://dx.doi.org/10.1126/science.1208813.
5. Zhang Y, Permar S, Sun Z. 2002. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 51:42-49. http://dx.doi.org/10.1099/0022-1317-51-1-42.
6. Vandal OH, Pierini LM, Schnappinger D, Nathan CF, Ehrt S. 2008. A membrane protein preserves intrabacterial pH in intraphagosomal Mycobacterium tuberculosis. Nat Med 14:849-854. http://dx.doi.org/10.1038/nm.1795.
7. MacMicking JD, Taylor GA, McKinney JD. 2003. Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science 302:654-659. http://dx.doi.org/10.1126/science.1088063.
8. Jindani A, Doré CJ, Mitchison DA. 2003. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 167:1348-1354. http://dx.doi.org/10.1164/rccm.200210-1125OC.
9. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Hutchings J, Burger DA, Schall R, Mendel CM. 2015. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med 191:943-953. http://dx.doi.org/10.1164/rccm.201410-1801OC.
10. Chigutsa E, Pasipanodya JG, Visser ME, van Helden PD, Smith PJ, Sirgel FA, Gumbo T, McIlleron H. 2015. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob Agents Chemother 59:38-45. http://dx.doi.org/10.1128/AAC.03931-14.
11. Grosset J, Truffot C, Fermanian J, Lecoeur H. 1982. Sterilizing activity of the main drugs on the mouse experimental tuberculosis. Pathol Biol (Paris) 30:444-448.
12. Hong Kong Chest Service/British Medical Research Council. 1991. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, threetimes-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis 143:700-706.
13. Mitchison DA, Fourie PB. 2010. The near future: improving the activity of rifamycins and pyrazinamide. Tuberculosis 90:177-181. http://dx.doi.org/10.1016/j.tube.2010.03.005.
14. Gumbo T, Lenaerts AJ, Hanna D, Romero K, Nuermberger E. 2015. Nonclinical models for antituberculosis drug development: a landscape analysis. J Infect Dis 211(Suppl 3):S83-S95. http://dx.doi.org/10.1093/infdis/jiv183.
15. Lenaerts A, Barry CE, Dartois V. 2015. Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev 264:288-307. http://dx.doi.org/10.1111/imr.12252.
16. Conte JE, Golden JA, Duncan S, McKenna E, Zurlinden E. 1999. Intrapulmonary concentrations of pyrazinamide. Antimicrob Agents Chemother 43:1329-1333.
17. Gumbo T, Dona CS, Meek C, Leff R. 2009. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 53:3197-3204. http://dx.doi.org/10.1128/AAC.01681-08.
18. Ahmad Z, Tyagi S, Minkowsk A, Almeida D, Nuermberger EL, Peck KM, Welch JT, Baughn AS, Jacobs WR, Grosset JH. 2012. Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis. Indian J Med Res 136:808-814.
19. Almeida DV, Tyagi S, Li S, Wallengren K, Pym AS, Ammerman NC, Bishai WR, Grosset JH. 2014. Revisiting anti-tuberculosis activity of pyrazinamide in mice. Mycobact Dis 4:145.
20. Rullas J, García JI, Beltrán M, Cardona PJ, Cáceres N, García-Bustos JF, Angulo-Barturen I. 2010. Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis. Antimicrob Agents Chemother 54:2262-2264. http://dx.doi.org/10.1128/AAC.01423-09.
21. Davis SL, Nuermberger EL, Um PK, Vidal C, Jedynak B, Pomper MG, Bishai WR, Jain SK. 2009. Noninvasive pulmonary [18F]-2-fluorodeoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother 53:4879-4884. http://dx.doi.org/10.1128/AAC.00789-09.
22. Harper J, Skerry C, Davis SL, Tasneen R, Weir M, Kramnik I, Bishai WR, Pomper MG, Nuermberger EL, Jain SK. 2012. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis 205:595-602. http://dx.doi.org/10.1093/infdis/jir786.
23. Driver ER, Ryan GJ, Hoff DR, Irwin SM, Basaraba RJ, Kramnik I, Lenaerts AJ. 2012. Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 56:3181-3195. http://dx.doi.org/10.1128/AAC.00217-12.
24. Lanoix JP, Lenaerts AJ, Nuermberger EL. 2015. Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis. Dis Model Mech 8:603-610. http://dx.doi.org/10.1242/dmm.019513.
25. Lanoix J-P, Ormond A, Dartois V, Nuermberger E. 2014. Antituberculosis activity of pyrazinamide varies by lesion type in C3HeB/FeJ mice, abstr 12. International Workshop on the Clinical Pharmacology of Tuberculosis Drugs. 5 September 2014, Washington, DC.
26. Lanoix J-P, Ormond A, Dartois V, Nuermberger E. 2014. Antituberculosis activity of pyrazinamide varies by lesion type in C3HeB/FeJ mice, abstr A-20. Abstr Intersci Conf Antimicrob Agents Chemother. 5 to 9 September 2014, Washington, DC.
27. Klinkenberg LG, Lee JH, Bishai WR, Karakousis PC. 2010. The stringent response is required for full virulence of Mycobacterium tuberculosis in guinea pigs. J Infect Dis 202:1397-1404. http://dx.doi.org/10.1086/656524.
28. Larsen MH, Biermann K, Tandberg S, Hsu T, Jacobs WR. 2007. Genetic manipulation of Mycobacterium tuberculosis. Curr Protoc Microbiol Chapter 10:Unit 10A.2. http://dx.doi.org/10.1002/9780471729259.mc10a02s6.
29. Ioerger TR, Feng Y, Ganesula K, Chen X, Dobos KM, Fortune S, Jacobs WR, Mizrahi V, Parish T, Rubin E, Sassetti C, Sacchettini JC. 2010. Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories. J Bacteriol 192:3645-3653. http://dx.doi.org/10.1128/JB.00166-10.
30. Via LE, Savic R, Weiner DM, Zimmerman MD, Prideaux B, Irwin SM, Lyon E, O'Brien P, Gopal P, Eum S, Lee M, Lanoix JP, Dutta NK, Shim T, Cho JS, Kim W, Karakousis PC, Lenaerts A, Nuermberger E, Barry CE III, Dartois V. 2015. Host-mediated bioactivation of pyrazinamide: implications for efficacy, resistance, and therapeutic alternatives. ACS Infect Dis 1:203-214. http://dx.doi.org/10.1021/id500028m.
31. Miotto P, Cabibbe AM, Feuerriegel S, Casali N, Drobniewski F, Rodionova Y, Bakonyte D, Stakenas P, Pimkina E, Augustynowicz-Kopeć E, Degano M, Ambrosi A, Hoffner S, Mansjö M, Werngren J, Rüsch-Gerdes S, Niemann S, Cirillo DM. 2014. Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study. mBio 5:e01819-01814. http://dx.doi.org/10.1128/mBio.01819-14.
32. Donald PR, Maritz JS, Diacon AH. 2012. Pyrazinamide pharmacokinetics and efficacy in adults and children. Tuberculosis 92:1-8. http://dx.doi.org/10.1016/j.tube.2011.05.006.
33. Kjellsson MC, Via LE, Goh A, Weiner D, Low KM, Kern S, Pillai G, Barry CE, Dartois V. 2012. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother 56:446-457. http://dx.doi.org/10.1128/AAC.05208-11.
34. Dartois V. 2014. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol 12:159-167. http://dx.doi.org/10.1038/nrmicro3200.
35. Prideaux B, Via LE, Zimmerman MD, Eum S, Sarathy J, O'Brien P, Chen C, Kaya F, Weiner DM, Chen PY, Song T, Lee M, Shim TS, Cho JS, Kim W, Cho SN, Olivier KN, Barry CE, Dartois V. 2015. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med 21:1223-1227. http://dx.doi.org/10.1038/nm.3937.
36. Kiem S, Schentag JJ. 2008. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 52:24-36. http://dx.doi.org/10.1128/AAC.00133-06.
37. Ahmad Z, Fraig MM, Bisson GP, Nuermberger EL, Grosset JH, Karakousis PC. 2011. Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. Antimicrob Agents Chemother 55:1527-1532. http://dx.doi.org/10.1128/AAC.01524-10.
38. Schaible UE, Sturgill-Koszycki S, Schlesinger PH, Russell DG. 1998. Cytokine activation leads to acidification and increases maturation of Mycobacterium avium-containing phagosomes in murine macrophages. J Immunol 160:1290-1296.
39. Jayaraman S, Song Y, Verkman AS. 2001. Airway surface liquid pH in well-differentiated airway epithelial cell cultures and mouse trachea. Am J Physiol Cell Physiol 281:C1504-C1511.
40. Bodem CR, Lampton LM, Miller DP, Tarka EF, Everett ED. 1983. Endobronchial pH. Relevance of aminoglycoside activity in gram-negative bacillary pneumonia. Am Rev Respir Dis 127:39-41.
41. Weiss C, Tabachnick J, Cohen HP. 1954. Mechanism of softening of tubercles. III. Hydrolysis of protein and nucleic acid during anaerobic autolysis of normal and tuberculous lung tissue in vitro. AMA Arch Pathol 57:179-193.
42. Weiser OL, Dye WE. 1956. Assay of Streptomycin in resected lung tissue. Conference on the chemotherapy of tuberculosis 12:198-201.
43. Fox W. 1981. Whither short-course chemotherapy? Br J Dis Chest 75:331-357. http://dx.doi.org/10.1016/0007-0971(81)90022-X.
44. Mitchison DA. 2000. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 4:796-806.
45. Aono A, Chikamatsu K, Yamada H, Kato T, Mitarai S. 2014. Association between pncA gene mutations, pyrazinamidase activity, and pyrazinamide susceptibility testing in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:4928-4930. http://dx.doi.org/10.1128/AAC.02394-14.
46. Timm J, Kurepina N, Kreiswirth BN, Post FA, Walther GB, Wainwright HC, Bekker LG, Kaplan G, McKinney JD. 2006. A multidrug-resistant, acr1-deficient clinical isolate of Mycobacterium tuberculosis is unimpaired for replication in macrophages. J Infect Dis 193:1703-1710. http://dx.doi.org/10.1086/504526.
47. Tan S, Sukumar N, Abramovitch RB, Parish T, Russell DG. 2013. Mycobacterium tuberculosis responds to chloride and pH as synergistic cues to the immune status of its host cell. PLoS Pathog 9:e1003282. http://dx.doi.org/10.1371/journal.ppat.1003282.
48. Irwin SM, Gruppo V, Brooks E, Gilliland J, Scherman M, Reichlen MJ, Leistikow R, Kramnik I, Nuermberger EL, Voskuil MI, Lenaerts AJ. 2014. Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas. Antimicrob Agents Chemother 58:4026-4034. http://dx.doi.org/10.1128/AAC.02565-14.